Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, has announced that its Chief Executive Officer, Jonathan Kaufman, will present a corporate overview and the final results from the Phase 2a trial of LP-10 in treating oral lichen planus. The presentation will take place at the Zacks SCR Life Sciences Virtual Investor Forum on September 18, 2025, at 12:30 PM EDT. This live, interactive online event will allow investors to ask questions in real-time, with an archived webcast available for those unable to attend. Interested participants are encouraged to pre-register and complete an online system check to facilitate their participation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipella Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH73021) on September 15, 2025, and is solely responsible for the information contained therein.